A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity.

@article{Gillies2011ALI,
  title={A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity.},
  author={Stephen D Gillies and Yan Ting Lan and Thore Hettmann and Beatrice Brunkhorst and Yaping Sun and Stefan M{\"u}ller and Kin-Ming Lo},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2011},
  volume={17 11},
  pages={3673-85}
}
PURPOSE The goal of the study was to engineer a form of interleukin 2 (IL-2) that, when delivered as a tumor-specific antibody fusion protein, retains the ability to stimulate an antitumor immune response via interaction with the high-affinity IL-2 receptor but has lower toxicity because of the reduced activation of the intermediate-affinity IL-2 receptor. EXPERIMENTAL DESIGN We investigated changes in the proposed toxin motif of IL-2 by introducing a D20T mutation that has little effect on… CONTINUE READING